One day after announcing that it plans to cut 9,000 jobs in a major restructuring, Novo Nordisk has told its employees that office work will be mandatory at the start of next year. More: Amid restructuring, Novo Nordisk directs employees
read moreWith Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the immunology duo can make the most
read more
Merck presents phase 3 STRIDE-13 trial results at ESCMID conference in Lisbon More: Capvaxive shows strong immune response in children at risk of pneumococcal disease Source: News
read more
New phase 4 results show sustained symptom relief and improved patient outcomes More: Lundbeck unveils migraine data for eptinezumab at international congress Source: News
read moreThe FDA has officially put its foot down on Intercept Pharmaceuticals’ rare liver disease drug Ocaliva, requesting that the company pull the med from the market and putting all of its related trials on a clinical hold. More: Intercept, after
read moreApproved 15 months ago as a pneumococcal disease vaccine for adults—and billed largely as the first shot designed for seniors—Merck’s Capvaxive has data supporting its potential in children and adolescents from a phase 3 trial. More: Despite being designed for
read more© 1994 - 2026 B.M. Pharmaceuticals